Related Experiment Video
Updated: Mar 18, 2026

Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
Improved glucose metabolism after gastric bypass: evolution of the paradigm
Dimitri J Pournaras1, Jonas Nygren2, Eva Hagström-Toft3
1The Norfolk and Norwich Oesophagogastric Cancer Centre, Norfolk and Norwich University Hospital, Colney Lane, Norwich, UK.
Background:
Glucose metabolism is improved in patients with type 2 diabetes after Roux-en-Y gastric bypass (RYGB).
Objectives:
To quantify the relative contribution of calorie restriction, rerouting of nutrients, and adipose tissue reduction.
Setting:
University Hospital.
Methods:
Fifteen diabetic patients, (47±9 yr, body mass index 41.3±4.2 kg/m2) were randomized to a 2-week very low-calorie diet (VLCD) regimen or normal diet before RYGB. A euglycemic-hyperinsulinemic clamp, indirect calorimetry, and a standard meal test were performed prediet, postdiet (preoperatively), and 2 weeks and 12 months postoperatively. The primary outcome was whole-body insulin sensitivity (M) measured with the clamp 2 weeks postoperatively.
Results:
In the VLCD group, after 2 weeks of calorie restriction, M improved (2.9±1.3 to 4.2±1.1 mg/kg/min, P = .005) with no further change at 2 weeks postoperatively. In the normal diet group 2 weeks postoperatively, M was similar to the VLCD group (4.7±1.7 versus 4.2±1.1, P = .61). One year postoperatively, M improved further in both groups. The improvement in insulin-stimulated glucose uptake after VLCD and RYGB was entirely accounted for by nonoxidative glucose disposal (NOGD), whereas weight loss at 1 year postoperatively was associated with an increase in NOGD and glucose oxidation. Postprandial glucose improved after VLCD (P<.05) and even more 2 weeks after RYGB (P<.05) with no further change after 1 year.
Conclusion:
Improved whole-body insulin sensitivity and postprandial glucose response occur early after RYGB. Low calorie intake and rerouting of nutrients contribute through distinct mechanisms. Weight loss contributes by increasing whole-body insulin sensitivity, including glucose oxidation and NOGD. These data suggest that the combination of different mechanisms is what makes RYGB an effective intervention for type 2 diabetes.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...

